About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Fingolimod Effect on Cytokine and Chemokine Levels

Fingolimod Effect on Cytokine and Chemokine Levels

NCT02373098·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novartis Pharmaceuticals

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Written informed consent must be obtained before the beginning of te study
2. Nonresponder RRMS patients
3. Last relapse of the patient should be at least 2 months before study entry.
4. Last interferon or glatiramer acetate dose of the patient should be at least 1 month before study entry.

You may not be if

1. Patients with secondary progressive MS.
2. Patients with known contraindications for fingolimod treatment.
3. Other coexistent autoimmune diseases
4. Pregnant or nursing (lactating) women

The record

StatusCompleted

PhasePhase 4

Taking part126

StartedMar 2015

UpdatedSep 30, 2019

Conditions

Relapsing Remitting Multiple Sclerosis

Where3

Novartis Investigative Site
Mecidiyeköy, Istanbul, Turkey (Türkiye)
Novartis Investigative Site
Üsküdar, Istanbul, Turkey (Türkiye)
Novartis Investigative Site
Istanbul, Turkey (Türkiye)